Biologics Spine Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data byTim AllenMay 13, 2025
Financial SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025) byJosh SandbergApril 8, 2025
Financial OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance byJosh SandbergJanuary 13, 2025
Financial Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 byJosh SandbergJanuary 13, 2025
Financial ATEC Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook byTim AllenJanuary 13, 2025
Financial Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results byTim AllenJanuary 9, 2025
Biologics Spine BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data byTim AllenNovember 13, 2024
Financial SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024) byJosh SandbergApril 10, 2024
Extremities Financial Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024 byTim AllenApril 4, 2024
Spine BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease byJosh SandbergFebruary 5, 2024
